Selexipag is a prostacyclin receptor agonist with high affinity for the prostacyclin receptor, leading to a reduction in adverse reactions compared to prostacyclin analogs [172] Selexipag has been shown to reduce the risk of death or PAH-related complications [187] in IPAH. The gene discussed is PTGIR; the disease is pulmonary arterial hypertension.